Electromyographic findings of the orbicularis oculi muscle in recurrent endonasal dacryocystorhinostomy failure: Orbicularis Oculi Function In Endonasal Dacryocystorhinostomy Failure
European Archives of Oto-Rhino-Laryngology, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s00405-026-10252-6
- Dergi Adı: European Archives of Oto-Rhino-Laryngology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: Endonasal dacryocystorhinostomy, Orbicularis oculi function, Electromyography
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To evaluate orbicularis oculi muscle function using electromyography in patients who developed recurrent epiphora and membranous neo-ostium obstruction after endonasal dacryocystorhinostomy (END-DCR) with documented initial patency and symptom improvement. Methods: Nineteen patients who underwent at least two END-DCR procedures on the same eye and later developed recurrent epiphora were included. Orbicularis oculi muscle activity was assessed using quantitative electromyography. Electrophysiological findings of the operated side were compared with the asymptomatic contralateral side and with healthy controls. Results: Motor unit potential (MUP) duration and amplitude were significantly increased on the operated side compared with both the asymptomatic side and the control group, consistent with neurogenic changes. No significant differences were observed between the asymptomatic side and controls. Conclusion: Despite the limited number of patients, the rarity and homogeneity of this clinical subgroup allowed detection of consistent and statistically robust electrophysiological differences. These findings provide preliminary evidence that orbicularis oculi dysfunction may contribute to recurrent failure after END-DCR with documented initial neo-ostium patency.